OTC : KHTRF

Knight Therapeutics Inc.

$6.85 USD

-$0.09 (-1.3%)

Volume
200
Average Volume
6.07K
Market Capitalization
$672.53M
P/E Ratio
64.79
Dividend Yield
0.00%
Price Target
Year High
$7.40
Year Low
$4.07
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.28
Company Overview

OTC

Samira Sakhia

Medical - Pharmaceuticals

Healthcare

KHTRF

830

CA

USD

http://www.gud-knight.com

514-484-4483

499053106

N/A

Liquidity Metrics

0.04

2.28

1.49

0.51

0.00

Sales & Valuation

$449.72M

1.71

1.17

8.66

1.10

Profitability

-$0.0539

-$5.37M

2.72%

3.91%

1.91%

1.42%

P/E Metrics

64.79

-0.01

-0.01

Analyst Price Target & Rating

Neutral

3/5

1 Analysts

%

Financial Health Scores

3.40

8/9

$234.91M

$1.04B

$246.25M

$26.22M

Key Metrics (TTM)

$854.79M

1.56

9.47

2.28

1.91%

2.08%

1.63%

11.82%

$5.26

106 days

Company Executives
Name Title
Arvind Utchanah Chief Financial Officer
Henrique Dias Global Vice President of Marketing
Jonathan Ross Goodman Executive Chairman
Leopoldo Bosano Vice-President of Manufacturing & Operations
Amal Khouri Chief Business Officer
Christine Poulin General Manager of Canada
Melanie Groleau Global Vice President of Medical & Clinical
Monica Percario Global Vice President of Regulatory & Quality
Samira Sakhia President, Chief Executive Officer & Director
Susan Caroline Emblem Global Vice President of Human Resources
Poll Results

No votes yet today — be the first to share your view!

About Knight Therapeutics Inc. (OTC:KHTRF) Stock

Knight Therapeutics Inc. operates as a specialized pharmaceutical enterprise, actively engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of a broad spectrum of pharmaceutical goods, consumer health solutions, and medical devices. Its operational footprint extends across Canada, Latin America, and other global markets. The company's extensive product offerings encompass treatments like Nerlynx, targeting extended adjuvant and metastatic breast cancer; Tafasitamab, prescribed for relapsed or refractory diffuse large B-cell lymphoma; and Pemigatinib, designed for metastatic cholangiocarcinoma. It also provides Trelstar for advanced prostate cancer and endometriosis-related pain; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancre ... atic adenocarcinoma; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima, utilized for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. Further expanding its therapeutic array, Knight Therapeutics supplies Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma. Other notable products include Zyvalix and Leprid, both aimed at metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Rembre for chronic myeloid leukemia; Ambisome and Cresemba, crucial for managing fungal infections; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for irritable bowel syndrome with constipation. The company's portfolio additionally features Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; and Bijuva for moderate to severe menopausal vasomotor symptoms in women with intact uteri. Rounding out its specialized treatments are Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for Pseudomonas aeruginosa lung infections in cystic fibrosis patients; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Beyond its core product activities, Knight Therapeutics Inc. also serves as a financier for other life science companies and allocates capital to life sciences venture capital funds. The organization was incorporated in 2013 and maintains its corporate headquarters in Montreal, Canada.

Knight Therapeutics Q2 Earnings Call Highlights

2026-08-09 20:04:50

Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects.

Knight Therapeutics Announces Repayment of Revolving Credit Facility

2026-06-17 17:30:00

MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders.

Knight Therapeutics Announces Launch of TAVALISSE® in Mexico

2026-05-27 18:00:00

MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1

Frequently Asked Questions

What is the current Knight Therapeutics Inc. (KHTRF) stock price?

Knight Therapeutics Inc.(OTC:KHTRF) stock price is $6.85 in the last trading session. During the trading session, KHTRF stock reached the peak price of $7.4 while $4.073 was the lowest point it dropped to. The percentage change in KHTRF stock occurred in the recent session was --1.3% while the dollar amount for the price change in KHTRF stock was -$0.09.

KHTRF's industry and sector of operation?

The OTC listed KHTRF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of KHTRF?

Arvind Utchanah | Chief Financial Officer
Henrique Dias | Global Vice President of Marketing
Jonathan Ross Goodman | Executive Chairman
Leopoldo Bosano | Vice-President of Manufacturing & Operations
Amal Khouri | Chief Business Officer

How many employees does KHTRF have?

Number of KHTRF employees currently stands at 830. KHTRF operates from 3400 De Maisonneuve Boulevard West, Montreal, QC H4M 2P2, CA.

Link for KHTRF official website?

Official Website of KHTRF is: http://www.gud-knight.com

How do I contact KHTRF?

KHTRF could be contacted at phone #514-484-4483 and can also be accessed through its website. KHTRF operates from 3400 De Maisonneuve Boulevard West, Montreal, QC H4M 2P2, CA.

How many shares of KHTRF are traded daily?

The average number of KHTRF shares traded daily for last 3 months was 6.07K.

What is the market cap of KHTRF currently?

The market value of KHTRF currently stands at $672.53M with its latest stock price at $6.85